BioPortUSA News and Event Updates

The team at BioPortUSA has been asked to present to a group of 17 Swiss Medical Device start-ups on what it takes to be successful in the USA including how to navigate the regulatory pathway. [...]

I was talking with a friend of mine in Germany who was raving about the benefits associated with the Hydrus Microstent (Ivantis) for glaucoma patients. This is a device that when combined with cataract surgery can help lower the eye pressure of a patient suffering from glaucoma. She focused on the features and benefits for both the patient and the physician. In the United States, a widely used alternative to the Hydrus Stent is the iStent from Glaucos. On July 2 the stock was trading at $82.45, on July 14th it was down to $57.82 and by July 26th it had dropped to $47.99. What happened? CMS (Center of Medicare and Medicaid Services) was rumored to slash the reimbursement from $500/procedure to $20. Since both the iStent and the Hydrus Mircostent use the same CPT code (billing code), there is a high likelihood that if this change by CMS goes through, that very few Ophthalmologist in the USA will use this product as part of their procedure because they will be making next to nothing. In Germany, no one is looking at the stock price or the reimbursement code! They are focused on what a great technology it is, and how it will help the patient.[...]

BioPortUSA attends event with Germany's largest trade association for the biotech industry.[...]

BioPortUSA announces joining the European American Chamber of Commerce in the United States. The mission of the eacc is to promote growth amongst private businesses on both sides of the Atlantic.[...]

Acutiy Strategic Partners is a comprehensive public affairs firm that specializes in building integrated strategies for life sciences companies, patients, and initiatives. In addition, they offer health care policy, advocacy, lobbying, and the formation of political action committees for clients. [...]